Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.
OConnor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW
Phase 2 2 : cagrilintide 1.2 + semaglutide 1.2 15.6% , 2.2% HbA1c
Muscle healing: Faster recovery from muscle detachment and crush injuries, with increased myofiber regeneration
The hepatoprotective effects of NaBPC157 were evaluated in comparison with reference standards such as bromocriptine, amantadine and somatostatin in various experimental models of liver injury in rats: 24 hour-bile duct and hepatic artery ligation, 48 hour-restraint stress and CCl 4 (a free radicals inducing agent) administration
Physicians may suggest opioids for severe or chronic back pain